Search: onr:"swepub:oai:DiVA.org:oru-109339" > Ototoxicity associa...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 02999naa a2200349 4500 | |
001 | oai:DiVA.org:oru-109339 | |
003 | SwePub | |
008 | 231020s2023 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1093392 URI |
024 | 7 | a https://doi.org/10.1186/s12879-023-08709-82 DOI |
040 | a (SwePub)oru | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Lange, Anna,d 1975-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Infectious Diseases4 aut0 (Swepub:oru)aalg |
245 | 1 0 | a Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection |
264 | 1 | b BioMed Central (BMC),c 2023 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment. The extended half-life, good penetration into bone and synovial fluid, and bactericidal activity against gram-positive bacteria, including those in biofilm, make dalbavancin an appealing choice for treatment of bone and joint infections in outpatient settings. However, we present a rare case of ototoxicity associated with off-label extended dalbavancin treatment of a prosthetic joint infection.CASE PRESENTATION: A 55-year-old man with a prosthetic joint infection of the shoulder underwent off-label extended dalbavancin treatment, receiving a cumulative dose of 2500 mg. The patient experienced a gradual onset of hearing loss following the first dose, leading to a diagnosis of bilateral sensorineural hearing loss that persisted 1 year after dalbavancin was discontinued.CONCLUSIONS: This case report highlights the importance of exercising caution when administering dalbavancin beyond approved dosing guidelines, and emphasizes the need for vigilance regarding the potential for ototoxicity. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
653 | a Dalbavancin | |
653 | a Ototoxicity | |
653 | a Prosthetic joint infection | |
700 | 1 | a Thunberg, Ulrica,d 1967-u Örebro universitet,Institutionen för hälsovetenskaper,Institutionen för medicinska vetenskaper,Department of Otorhinolaryngology4 aut0 (Swepub:oru)uatg |
700 | 1 | a Söderquist, Bo,d 1955-u Örebro universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:oru)bost |
710 | 2 | a Örebro universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t BMC Infectious Diseasesd : BioMed Central (BMC)g 23:1q 23:1x 1471-2334 |
856 | 4 | u https://doi.org/10.1186/s12879-023-08709-8y Fulltext |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-109339 |
856 | 4 8 | u https://doi.org/10.1186/s12879-023-08709-8 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view